Search Results for "Albumin Bound Paclitaxel And Production"
Matching Channels
Duchenne muscular dystrophy - DMD
Duchenne muscular dystrophy (DMD) is a severely debilitating childhood neuromuscular disease that affects 1 in 3,500 live male births. This rare disease is caused by mutations in the dystrophin gene...
Vasodilation refers to the widening of blood vessels resulting from relaxation of smooth muscle cells within the vessel walls, particularly in the large arteries, smaller arterioles and large veins....
Matching News
Albumin-Bound Paclitaxel Approved for Lung Cancer
The albumin-bound form of paclitaxel, already approved for breast cancer, is now available for use in nonsmall cell lung cancer. FDA Approvals
Celgene advances nab-paclitaxel development in difficult-to-treat cancers
Celgene International Sàrl, a subsidiary of Celgene Corporation, has reached a number of milestones related to the development of ABRAXANE (paclitaxel protein-bound particles for injectable suspensio...
Nab-paclitaxel was well tolerated in this population of patients with pretreated advanced urothelial cancer with an encouraging tumour response. These results warrant further study of nab-paclitaxel i...
Celgene buoyant on positive pancreatic cancer Phase III and filing plans for Abraxane
Celgene's announcement of plans to file for approval of Abraxane (paclitaxel protein-bound particles for injectable suspension; albumin bound) for pancreatic cancer in the US, Europe and other markets...
FDA Approves Abraxane for NSCLC and expands indication for Actemra
The US Food and Drug Administration on Friday approved biotech firm Celgene's (Nasdaq: CELG) Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line...
Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line...
Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer
Celgene International Sàrl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combi...
Celgene's Abraxane meets primary endpoints in pancreatic cancer study
In what was some good news on the pancreatic cancer scene, the European subsidiary of US biotech firm Celgene Corp (Nasdaq: CELG) says that its Phase III study of Abraxane (paclitaxel protein-bound pa...
Matching PubMed Articles
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is delivered to tumors and increases antitumor activity compared with solvent-based paclitaxel. However, in a clinical trial, higher and lower ra...
Aim: The COSTABRAX study evaluated the cost-effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) versus polyethylated castor oil-based standard paclitaxel (sb-paclitaxel) in the tre...
Background: Neoadjuvant anthracycline/taxane combinations, with or without gemcitabine, produce pathologic complete responses (pCRs) in 15%-25% of patients. In this multicenter phase II study, we atte...
Cystoid Macular Edema Secondary to Nanoparticle Albumin-Bound Paclitaxel Therapy.
The authors report a case of nanoparticle albumin-bound paclitaxel-induced cystoid macular edema (CME) without fluorescein angiographic leakage in a patient being treated for metastatic breast cancer....
There is increasing evidence that paclitaxel and carboplatin are clinically active in the treatment of metastatic melanoma (MM). ABI-007 is an albumin-bound formulation of paclitaxel that has demonstr...
